Moderna jumps premarket after Phase 3 trial, Target slides By Investing.com

•2mo ago

Moderna jumps premarket after Phase 3 trial, Target slides By Investing.com

Tap title to read story

0:00 / 1:18

Moderna shares jumped as much as 96% in premarket trading Wednesday after the drugmaker and Merck announced positive Phase 3 results for their personalized mRNA melanoma therapy, intismeran autogene (mRNA-4157/V940), combined with Merck's Keytruda . The INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma, marking the first positive Phase 3 results for an individualized neoantigen therapy . Meanwhile, Target shares fell 4% despite beating expectations with a 3.8% comparable sales increase and $4.11 adjusted EPS, as investors focused on tariff-related benefits—a nearly $1 billion quarterly boost—and the company's underlying profit outlook excluding those gains . U.S. stock futures traded mixed amid a deepening global bond selloff pushing the 30-year Treasury yield to 5.33%, a 19-year high, and oil prices above $90 a barrel on Middle East tensions .

Published 2026-08-19 14:18:44 UTC · Published by JQJO

Prepared by Ayesha A. · AI assisted

More context

Timeline

Past Events:
On 2016, Merck and Moderna began their cancer vaccine collaboration.
On 2024, FDA rejected Moderna's initial accelerated approval request for intismeran.
On June 2026, Phase 2 data showed 49% recurrence risk reduction at five years.
On Aug 1, 2026, Target's Q2 quarter ended with net sales of $26.5 billion.
On Aug 15, 2026, U.S. retail sales dropped 0.6% in July missing forecasts.
On Aug 17, 2026, U.S.-Iran ceasefire expired reigniting Middle East tensions.
On Aug 17, 2026, 30-year Treasury yield hit 5.33% highest since 2007.
Present Events:
On Aug 19, 2026, Moderna premarket stock surged as much as 96% .
On Aug 19, 2026, Target shares fell 4% despite earnings beat and raised guidance .
On Aug 19, 2026, global bond selloff continued with 10-year yield near 4.74% .
Future Predictions:
Moderna and Merck will engage regulators on filing submissions for approval.
Detailed trial data will be presented at an upcoming international medical meeting.
Overall survival analysis continues; additional trial results expected down the line.
Moderna's melanoma therapy could generate over $6 billion in annual sales.
Same approach may be extendable to lung, kidney, and bladder cancer.
Middle East diplomatic resolution could pull crude and yields off highs.

Why it matters

Immediate US impact: Mixed market signals: biotech rally offsets tech pressure from bonds. Long-term US impact: Personalized mRNA cancer therapy could revolutionize oncology treatment paradigms. Affected groups: Melanoma patients, biotech investors, retail workers, tariff-sensitive consumers, and bondholders. Reader priority: Verify clinical significance versus investor hype and tariff impacts on retail.

Coverage notes

Left: Emphasizes healthcare access, affordability, and equitable cancer treatment availability concerns. Center: Focuses on clinical trial data, market reactions, and balanced corporate performance reporting. Right: Highlights market-driven innovation, shareholder value, and deregulation enabling medical breakthroughs.